Tang Capital Management ANIP Position
Active4-Fund ConvergenceTang Capital Management increased their position in ANI PHARMACEUTICALS INC (ANIP) in Q4 2025, holding $38.0M worth of shares across 481,437 shares.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
ANIP is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 20.0% of float with 9.7 days to cover, indicating significant bearish positioning against Tang Capital's long thesis.
About ANI PHARMACEUTICALS INC
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Full company profile →Short Interest
20.0%
9.7 days to cover
Tang Capital Management ANIP Position History
Frequently Asked Questions
Does Tang Capital Management own ANIP?
Yes. As of Q4 2025, Tang Capital Management holds 481,437 shares of ANI PHARMACEUTICALS INC (ANIP) valued at $38.0M. This data comes from their SEC 13F filing.
How many hedge funds own ANIP?
4 specialist biotech hedge funds currently hold ANIP, including Deep Track Capital, Driehaus Capital, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy ANIP?
Tang Capital Management's position in ANIP was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's ANIP position increasing or decreasing?
Tang Capital Management increased their ANIP position in the most recent quarter, adding 163,937 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ANIPCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →